Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

6 Months Ended

Feb. 29, 2024

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total
Marketable Securities	$	87,699	$	87,699	$	-	$	-	$	87,699

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total
Marketable Securities	$	125,642	$	125,642	$	-	$	-	$	125,642